Diligence memo · auto-generated · as of July 2, 2026
Mizar Therapeutics, Inc.
Mizar Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Mizar Therapeutics, Inc. operates in Pharma, based in WOODS HOLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mizar Therapeutics, Inc. has raised $519K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $519K on 2025-05-09.
Most recent recorded round closed around 2025-05-09.
Valuation (modeled)modeled
Provath models Mizar Therapeutics, Inc. at approximately $1.4M (range $290K–$3.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.23× the median modeled value of Pre-Seed Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 31% of Pharma peers (310 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: ReEngage Therapeutics, Inc., King Therapeutics LLC, Dnp Therapeutics Inc, Protibea Therapeutics, Inc., Thiogenesis Therapeutics, Corp..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.